article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

Anthrax is a rare, yet severe disease caused by the bacterium B. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. These antibodies play a crucial role in providing protection by effectively neutralizing the cytotoxic lethal toxin and edema toxin of B.

article thumbnail

New Research Shows IBS Symptoms May be Caused by Gut Infections

XTalks

To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar

pharmaphorum

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.

article thumbnail

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

pharmaphorum

With ASP3772, GSK could offer a shot with broader coverage of pneumococcal serotypes than any of its rivals, and which also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype.

article thumbnail

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.

The Pharma Data

Affinivax’s most advanced vaccine candidate (AFX3772) includes 24 pneumococcal polysaccharides plus two conserved pneumococcal proteins (compared to up to 20 serotypes in currently approved vaccines). The bacterium Streptococcus pneumoniae causes pneumococcal disease. About Pneumococcal disease.

article thumbnail

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.

The Pharma Data

Affinivax’s most advanced vaccine candidate (AFX3772) includes 24 pneumococcal polysaccharides plus two conserved pneumococcal proteins (compared to up to 20 serotypes in currently approved vaccines). The bacterium Streptococcus pneumoniae causes pneumococcal disease. CAGR: Compound Annual Growth Rate; **CER: Constant Exchange Rate.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Johnson & Johnson’s Top 5 Best-Selling Drugs of 2022: 1) Stelara (ustekinumab) Stelara is an immunosuppressant biologic therapy that blocks the IL-12 and IL-23 proteins that play a role in plaque psoriasis and Crohn’s disease. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells).

Sales 98